Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer s Disease at the Alzheimer s Association International Conference (AAIC) 2023 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
The FDA today approved a new therapy for early Alzheimer s disease that appears to modestly slow the progression of the disease that affects more than 6.5 million Americans.
On Thursday, the Food and Drug Administration made a decision that’s likely to have a major impact on the landscape of Alzheimer’s disease research. The agency issued a full-throated traditional approval of the drug Leqembi, developed by the companies Eisai and Biogen. The drug is the first of its class to receive such approval and is intended to slow down the progression of the neurodegenerative disease.
A genetic predisposition for Alzheimer s disease has been associated with an increased risk for epilepsy, and vice versa, results of a large genome-wide association study (GWAS) show.